Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center
暂无分享,去创建一个
B. Pasini | P. Quaglino | S. Ribero | G. Avallone | L. Mastorino | F. Cavallo | G. Roccuzzo | Silvia Giordano | Thomas Granato | S. Giordano
[1] B. Pasini,et al. BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome. , 2022, Melanoma research.
[2] I. Zalaudek,et al. Extensive “halo naevi” phenomenon and regression of melanin during nivolumab treatment in metastatic melanoma: A predictor of a better outcome? , 2022, Dermatologic therapy.
[3] N. Serman,et al. Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review , 2022, Bosnian journal of basic medical sciences.
[4] M. Aglietta,et al. Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma , 2022, Journal of clinical medicine.
[5] P. Queirolo,et al. Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials , 2021, Journal of clinical medicine.
[6] J. Valls,et al. Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification , 2021, Acta dermato-venereologica.
[7] L. Alós,et al. Molecular Markers and Targets in Melanoma , 2021, Cells.
[8] S. Puig,et al. Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management , 2021, Journal of clinical medicine.
[9] A. Geller,et al. Epidemiology of Melanoma. , 2021, Hematology/oncology clinics of North America.
[10] H. Soyer,et al. Germline and somatic albinism variants in amelanotic/hypomelanotic melanoma: Increased carriage of TYR and OCA2 variants , 2020, PloS one.
[11] J. Welborn,et al. Germline mutations predisposing to melanoma , 2020, Journal of cutaneous pathology.
[12] C. Massone,et al. Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients , 2020, Journal of Translational Medicine.
[13] P. Ascierto,et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] A. Scope,et al. Dermoscopy of naevi in patients with oculocutaneous albinism , 2019, Clinical and experimental dermatology.
[15] K. Liopyris,et al. Dermoscopy: A Review of the Structures That Facilitate Melanoma Detection , 2019, The Journal of the American Osteopathic Association.
[16] J. Malvehy,et al. Melanocortin 1 receptor (MC1R) polymorphisms’ influence on size and dermoscopic features of nevi , 2018, Pigment cell & melanoma research.
[17] J. Malvehy,et al. Amelanotic melanoma in oculocutaneous albinism: a genetic, dermoscopic and reflectance confocal microscopy study , 2017, The British journal of dermatology.
[18] Giuseppe Argenziano,et al. A meta‐analysis of nevus‐associated melanoma: Prevalence and practical implications , 2017, Journal of the American Academy of Dermatology.
[19] C. Longo,et al. 592 Clinical, dermoscopic and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation , 2017 .
[20] C. Shea,et al. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature , 2017, JAMA dermatology.
[21] M A Weinstock,et al. The global burden of melanoma: results from the Global Burden of Disease Study 2015 , 2017, The British journal of dermatology.
[22] K. Peris,et al. Characterization of melanoma susceptibility genes in high-risk patients from Central Italy , 2017, Melanoma research.
[23] S. Kawana,et al. Melanotic Malignant Melanoma in Oculocutaneous Albinism Type 4. , 2017, Acta dermato-venereologica.
[24] N. Gruis,et al. The absence of multiple atypical nevi in germline CDKN2A mutations: Comment on "Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome". , 2016, Journal of the American Academy of Dermatology.
[25] P. Galan,et al. The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. , 2016, The Journal of clinical endocrinology and metabolism.
[26] Nicola D. Roberts,et al. Germline MC1R status influences somatic mutation burden in melanoma , 2016, Nature Communications.
[27] M. Askarian-Amiri,et al. Signaling Pathways in Melanogenesis , 2016, International journal of molecular sciences.
[28] D. Glass,et al. Genetic epidemiology of melanoma , 2016, European Journal of Dermatology.
[29] S. Puig,et al. Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. , 2016, The Journal of investigative dermatology.
[30] H. Tsao,et al. Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling. , 2016, Journal of the American Academy of Dermatology.
[31] P. Ascierto,et al. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. , 2016, Journal of the American Academy of Dermatology.
[32] J. Little,et al. MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project , 2015, British Journal of Cancer.
[33] A. Andrén-sandberg,et al. Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer. , 2015, JAMA surgery.
[34] J. Malvehy,et al. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom , 2014, Hereditary cancer in clinical practice.
[35] Carlo Riccardo Rossi,et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. , 2014, In vivo.
[36] Sikandar G. Khan,et al. High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients , 2014, Pigment cell & melanoma research.
[37] S. Rosso,et al. MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors , 2014, Pigment cell & melanoma research.
[38] O. Abbas,et al. Cutaneous Malignant Melanoma: Update on Diagnostic and Prognostic Biomarkers , 2014, The American Journal of dermatopathology.
[39] J. Malvehy,et al. Distribution of MC1R variants among melanoma subtypes: p.R163Q is associated with lentigo maligna melanoma in a Mediterranean population , 2013, The British journal of dermatology.
[40] K. Hemminki,et al. Variants at the 9p21 locus and melanoma risk , 2013, BMC Cancer.
[41] Giovanni Pellacani,et al. CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients , 2013, Experimental dermatology.
[42] N. Hayward,et al. Prevalence of germline BAP1 mutation in a population‐based sample of uveal melanoma cases , 2013, Pigment cell & melanoma research.
[43] P. Queirolo,et al. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history , 2013, Pigment cell & melanoma research.
[44] Thomas Krausz,et al. BAP1 and cancer , 2013, Nature Reviews Cancer.
[45] R. Wolterbeek,et al. Melanocortin 1 receptor (MC1R) variants in high melanoma risk patients are associated with specific dermoscopic ABCD features. , 2012, Acta dermato-venereologica.
[46] L. Larue,et al. PTEN and melanomagenesis. , 2012, Future oncology.
[47] Peter Boyle,et al. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.
[48] L. Chin,et al. Melanoma: from mutations to medicine. , 2012, Genes & development.
[49] Ivana K. Kim,et al. Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families , 2012, PloS one.
[50] K. Brown,et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.
[51] S. Puig,et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.
[52] H. Putter,et al. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. , 2011, Journal of the American Academy of Dermatology.
[53] J. Malvehy,et al. Early stages of melanoma on the limbs of high-risk patients: clinical, dermoscopic, reflectance confocal microscopy and histopathological characterization for improved recognition. , 2011, Acta dermato-venereologica.
[54] J. Barrett,et al. Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK , 2011, Journal of Medical Genetics.
[55] Gail M Williams,et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] S. Puig,et al. Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study , 2010, Journal of the National Cancer Institute.
[57] K. Nielsen,et al. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype , 2010, Melanoma research.
[58] A. Marghoob,et al. Defining the patient at high risk for melanoma , 2010, International journal of dermatology.
[59] A. Halpern,et al. Selection criteria for genetic assessment of patients with familial melanoma. , 2009, Journal of the American Academy of Dermatology.
[60] J. Lundeberg,et al. MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters , 2009, Pigment cell & melanoma research.
[61] J. Malvehy,et al. Dermoscopic features of melanomas associated with MC1R variants in Spanish CDKN2A mutation carriers , 2009, The British journal of dermatology.
[62] F. Sera,et al. MC1R variants, melanoma and red hair color phenotype: A meta‐analysis , 2008, International journal of cancer.
[63] N. Hayward,et al. Cutaneous melanoma susceptibility and progression genes. , 2005, Cancer letters.
[64] L. Cannon-Albright,et al. Population-based analysis of prognostic factors and survival in familial melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] J. Malvehy,et al. Role of the CDKN2A locus in patients with multiple primary melanomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] L. Cannon-Albright,et al. Longitudinal assessment of the nevus phenotype in a melanoma kindred. , 2004, The Journal of investigative dermatology.
[67] C. Lebbé,et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure , 2004, Journal of Medical Genetics.
[68] Hensin Tsao,et al. A population‐based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors , 2003, Cancer.
[69] Florence Demenais,et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. , 2002, Journal of the National Cancer Institute.
[70] W. Clark,et al. A natural history of melanomas and dysplastic nevi , 2002, Cancer.
[71] P. Aegerter,et al. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. , 2001, Archives of dermatology.
[72] R. Willemze,et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. , 2001, The Journal of investigative dermatology.
[73] J. Struewing,et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. , 2000, Journal of the National Cancer Institute.
[74] D. Bishop,et al. Mutation screening of the CDKN2A promoter in melanoma families , 2000, Genes, chromosomes & cancer.
[75] W. Cavenee,et al. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[76] J. Mark Elwood,et al. Melanoma and sun exposure: An overview of published studies , 1997, International journal of cancer.
[77] N. Martin,et al. Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. , 1997, Human molecular genetics.
[78] M. Qadir,et al. Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment. , 2020, Critical reviews in eukaryotic gene expression.
[79] D. Duffy,et al. Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. , 2014, The Journal of investigative dermatology.
[80] Jeffrey E. Lee,et al. Natural and orthogonal model for estimating gene–gene interactions applied to cutaneous melanoma , 2013, Human Genetics.
[81] P. Boyle,et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. , 2005, European journal of cancer.
[82] P. Boyle,et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. , 2005, European journal of cancer.
[83] D. Duffy,et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? , 2000, American journal of human genetics.